NYKODE THERAPEUTICS ASA: årsregnskap 2023 vs 2022
Grew 48% on revenue, fresh owner capital
approved 2024-04-18; registry 2024-08-12; journal 2024 656914
Summary
What changed
Comparing Årsregnskap 2023 with 2022 for NYKODE THERAPEUTICS ASA. Revenue 9.03m NOK → 13.36m NOK (+48.0%). Net result -41.68m NOK → -33.39m NOK. Equity 158.83m NOK → 174.8k NOK.
On the constructive side: revenue rose; net result improved; owners injected capital. Pressures included: operating result weakened; equity eroded; cash fell.
Also worth watching: thin equity buffer; payroll increased; book investments changed. All figures are taken from the published annual accounts for NYKODE THERAPEUTICS ASA.
At a glance
Scorecard
What improved
-
↑
Revenue rose
Operating income / revenue moved from 9.03m NOK to 13.36m NOK (+48.0% YoY). Calculated
-
↑
Net result improved
Net result -41.68m NOK → -33.39m NOK (net margin -461.6% → -249.9%). Calculated
-
↑
Owners injected capital
Paid-in equity rose 83.66m NOK → 141.63m NOK (+57.98m NOK). Reported fact
What deteriorated
-
↓
Operating result weakened
Operating result -52.15m NOK → -56.48m NOK (op. margin -577.6% → -422.7%). Calculated
-
↓
Equity eroded
Book equity 158.83m NOK → 174.8k NOK (equity ratio 71.0% → 0.1%). Calculated
-
↓
Cash fell
Bank deposits 205.70m NOK → 161.54m NOK (-21.5% YoY). Calculated
Things to notice
-
·
Thin equity buffer
Equity ratio is 0.1% of assets — limited loss-absorbing capacity on a stand-alone basis. Interpretation
-
·
Payroll increased
Salary cost 11.77m NOK → 18.33m NOK (130% → 137% of revenue). Calculated
-
·
Book investments changed
Investment / intangible book value 83.0k NOK → 4.32m NOK. Reported fact